Hikal
Hikal Limited, a prominent player in the pharmaceutical and agrochemical sectors, is headquartered in India. Established in 1988, the company has made significant strides in providing high-quality active pharmaceutical ingredients (APIs) and intermediates, alongside a diverse range of agrochemical products. With a strong operational presence across India and international markets, Hikal has positioned itself as a trusted partner for global pharmaceutical and agricultural companies. Hikal's core offerings include custom synthesis, contract manufacturing, and a robust portfolio of APIs that cater to various therapeutic areas. The company is recognised for its commitment to quality and innovation, which has earned it several industry accolades. As a leader in its field, Hikal continues to drive advancements in sustainable practices and technology, solidifying its reputation as a key contributor to the global healthcare and agriculture landscape.
DitchCarbon Score
How does Hikal's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikal's score of 35 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hikal's reported carbon emissions
In 2024, Hikal Limited reported total carbon emissions of approximately 21,410,710 kg CO2e for Scope 1 and about 67,287,010 kg CO2e for Scope 2, resulting in a combined total of approximately 88,697,720 kg CO2e. This marks a slight decrease from 2023, where emissions were approximately 26,793,240 kg CO2e for Scope 1 and about 67,737,300 kg CO2e for Scope 2, totalling around 94,530,540 kg CO2e. Hikal has set an ambitious target to achieve a 30% reduction in both Scope 1 and Scope 2 emissions by the end of the 2027-28 fiscal year, using 2022-23 levels as a baseline. This commitment reflects their dedication to decarbonisation within the pharmaceuticals, biotechnology, and life sciences sector. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Hikal's emissions data is not cascaded from any parent organisation, ensuring that their reported figures are independently sourced.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 57,457,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hikal is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
